Congenital Zika Syndrome (Zika Virus)
Overview
Plain-Language Overview
Congenital Zika Syndrome (CZS) is a condition that affects babies born to mothers infected with the Zika virus during pregnancy. It primarily impacts the nervous system, especially the developing brain. Babies with this syndrome often have a very small head size, known as microcephaly, which can lead to developmental delays and intellectual disabilities. Other common problems include difficulties with movement, seizures, and vision or hearing impairments. The syndrome results from the virus damaging brain cells while the baby is still in the womb. This condition can cause lifelong challenges in learning, growth, and physical abilities.
Clinical Definition
Congenital Zika Syndrome (CZS) is a pattern of birth defects caused by in utero infection with the Zika virus, a flavivirus transmitted primarily by Aedes mosquitoes. The core pathology involves viral neurotropism leading to destruction of neural progenitor cells, resulting in severe microcephaly, cerebral calcifications, and cortical malformations. Additional features include ocular abnormalities, arthrogryposis, and hypertonia. The syndrome is clinically significant due to its association with profound neurodevelopmental impairment and increased risk of mortality. Diagnosis is supported by maternal history of Zika exposure during pregnancy and characteristic fetal or neonatal findings. The condition highlights the importance of vector control and prenatal screening in endemic areas.
Inciting Event
Maternal infection with Zika virus, typically via Aedes mosquito bite, during pregnancy initiates fetal infection.
Sexual transmission of Zika virus from an infected partner to a pregnant woman can also trigger fetal infection.
Maternal viremia allows transplacental passage of the virus to the developing fetus.
Intrauterine infection during critical periods of neurodevelopment leads to congenital abnormalities.
Latency Period
Symptoms and congenital abnormalities typically manifest at birth or are detected on prenatal ultrasound in the second or third trimester.
There is a variable latency from maternal infection to fetal brain damage, often weeks to months.
Microcephaly and other brain abnormalities may be identified during routine mid-pregnancy ultrasound screening.
Some neurological deficits may become apparent only after birth during early infancy.
Diagnostic Delay
Asymptomatic maternal infection often leads to missed or delayed diagnosis of fetal involvement.
Overlap of clinical features with other congenital infections can cause diagnostic confusion.
Limited access to Zika virus PCR and serologic testing in endemic regions delays confirmation.
Prenatal ultrasounds may not detect subtle brain abnormalities early in gestation.
Lack of awareness about Congenital Zika Syndrome in non-endemic areas contributes to delayed recognition.
Clinical Presentation
Signs & Symptoms
Severe microcephaly present at birth or developing postnatally
Seizures due to cortical malformations and brain injury
Feeding difficulties and poor suck reflex
Irritability and hyperexcitability reflecting central nervous system involvement
Visual impairment from retinal and optic nerve abnormalities
History of Present Illness
Pregnant women may report recent febrile illness with rash, conjunctivitis, and arthralgia consistent with Zika virus infection.
Prenatal ultrasounds reveal microcephaly, intracranial calcifications, and ventriculomegaly in the fetus.
Newborns present with severe microcephaly, hypertonia, irritability, and seizures.
Additional findings include ocular abnormalities, hearing loss, and arthrogryposis.
Neurological symptoms progress with developmental delay and motor impairments in infancy.
Past Medical History
Maternal history of recent travel to or residence in Zika-endemic regions is critical.
Previous infections with other flaviviruses such as dengue may be noted but do not prevent Zika infection.
Lack of prior immunization or prophylaxis against mosquito-borne illnesses is common.
No specific maternal chronic illnesses are directly linked to increased risk of congenital Zika syndrome.
History of prior adverse pregnancy outcomes may be relevant but is not specific.
Family History
There is no known heritable genetic predisposition to congenital Zika syndrome.
Family history is typically negative for similar congenital malformations unless due to other causes.
No familial syndromes overlap with the pattern of brain abnormalities seen in congenital Zika syndrome.
Recurrence risk in subsequent pregnancies depends on maternal exposure rather than genetics.
Genetic counseling focuses on environmental exposure rather than inherited mutations.
Physical Exam Findings
Microcephaly with a head circumference significantly below the mean for age and sex
Craniofacial disproportion including prominent occiput and overlapping sutures
Hypertonia and increased muscle tone with spasticity
Arthrogryposis characterized by joint contractures and limited range of motion
Ocular abnormalities such as macular scarring and pigmentary retinal mottling
Diagnostic Workup
Diagnostic Criteria
Diagnosis of congenital Zika syndrome is established by identifying microcephaly and characteristic brain imaging abnormalities such as intracranial calcifications and cortical malformations on ultrasound, CT, or MRI. Confirmation requires detection of Zika virus RNA by RT-PCR in maternal, fetal, or neonatal samples or positive Zika virus IgM antibodies in the newborn. A history of maternal Zika virus exposure during pregnancy supports the diagnosis. Additional findings like ocular defects and arthrogryposis further support the clinical diagnosis.
Pathophysiology
Key Mechanisms
Vertical transmission of Zika virus leads to direct infection of neural progenitor cells, causing impaired neurogenesis and microcephaly.
Zika virus induces apoptosis and cell cycle arrest in fetal neural cells, disrupting normal brain development.
Infection triggers neuroinflammation and gliosis, contributing to brain tissue damage and calcifications.
Disruption of cortical development results in lissencephaly, ventriculomegaly, and other structural brain abnormalities.
Placental infection impairs nutrient and oxygen delivery, exacerbating fetal brain injury.
| Involvement | Details |
|---|---|
| Organs | Brain is the primary organ affected, with microcephaly, ventriculomegaly, and cortical malformations as hallmark features. |
Eyes are commonly involved, with congenital glaucoma, optic nerve hypoplasia, and retinal lesions. | |
Musculoskeletal system shows arthrogryposis due to fetal akinesia from central nervous system damage. | |
| Tissues | Cerebral cortex tissue is severely affected, showing calcifications, cortical thinning, and disrupted architecture. |
Placental tissue serves as a reservoir and transmission route for Zika virus from mother to fetus. | |
Ocular tissue can be damaged, leading to chorioretinal atrophy and visual impairment. | |
| Cells | Neural progenitor cells are targeted by the Zika virus, leading to impaired neurogenesis and microcephaly. |
Microglia become activated in response to viral infection, contributing to neuroinflammation and neuronal damage. | |
Astrocytes are infected and contribute to disruption of the blood-brain barrier and neurodevelopmental abnormalities. | |
| Chemical Mediators | Type I interferons are critical antiviral cytokines involved in the host immune response to Zika virus infection. |
Proinflammatory cytokines such as IL-6 and TNF-alpha mediate neuroinflammation and contribute to brain injury. | |
Viral RNA acts as a pathogen-associated molecular pattern triggering innate immune activation in neural tissues. |
Treatments
Pharmacological Treatments
Non-pharmacological Treatments
Provide comprehensive supportive care including physical, occupational, and speech therapy to address neurodevelopmental delays.
Use nutritional support and feeding assistance for infants with microcephaly and swallowing difficulties.
Implement early intervention programs to optimize developmental outcomes and manage neurological impairments.
Monitor and manage seizures with appropriate antiepileptic drugs as needed.
Provide multidisciplinary care involving neurology, ophthalmology, and audiology for associated sensory deficits.
Prevention
Pharmacological Prevention
No approved antiviral medications or vaccines currently exist for Zika virus prevention
Supportive care remains the mainstay for managing symptoms and complications
Experimental vaccine candidates are under development but not yet available
Use of acetaminophen to manage fever and discomfort during acute infection
Avoidance of NSAIDs until dengue virus coinfection is excluded to prevent hemorrhagic complications
Non-pharmacological Prevention
Avoidance of mosquito exposure through insect repellents and protective clothing
Elimination of standing water to reduce Aedes mosquito breeding sites
Use of bed nets and window screens in endemic areas
Travel advisories for pregnant women to avoid Zika-endemic regions
Prenatal screening and ultrasound monitoring for early detection of fetal abnormalities
Outcome & Complications
Complications
Severe neurodevelopmental impairment with profound intellectual disability
Recurrent seizures that may be difficult to control
Feeding and swallowing difficulties leading to failure to thrive
Respiratory complications from central apnea or aspiration pneumonia
Orthopedic deformities such as scoliosis and joint contractures
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Congenital Zika Syndrome (Zika Virus) versus Cytomegalovirus (CMV) Congenital Infection
Congenital Zika Syndrome (Zika Virus) | Cytomegalovirus (CMV) Congenital Infection |
|---|---|
Diffuse intracranial calcifications with prominent microcephaly | Periventricular calcifications and ventriculomegaly |
Maternal Zika virus infection during pregnancy | Maternal primary CMV infection during pregnancy |
Positive Zika virus RNA by RT-PCR in maternal or infant serum or urine | Positive CMV PCR or culture from urine or saliva |
Congenital Zika Syndrome (Zika Virus) versus Toxoplasmosis Congenital Infection
Congenital Zika Syndrome (Zika Virus) | Toxoplasmosis Congenital Infection |
|---|---|
Predominantly subcortical calcifications with microcephaly | Diffuse intracranial calcifications with hydrocephalus |
Maternal travel to or residence in Zika-endemic areas | Maternal exposure to cat feces or undercooked meat |
Positive Zika virus RNA by RT-PCR in maternal or infant serum or urine | Positive Toxoplasma gondii IgM or PCR in infant serum or CSF |
Congenital Zika Syndrome (Zika Virus) versus Congenital Rubella Syndrome
Congenital Zika Syndrome (Zika Virus) | Congenital Rubella Syndrome |
|---|---|
Severe cortical thinning and calcifications | White matter abnormalities and periventricular cysts |
Maternal Zika virus infection during pregnancy | Maternal rubella infection during first trimester |
Positive Zika virus RNA by RT-PCR in maternal or infant serum or urine | Positive rubella IgM or PCR in infant serum |
Congenital Zika Syndrome (Zika Virus) versus Fetal Alcohol Syndrome
Congenital Zika Syndrome (Zika Virus) | Fetal Alcohol Syndrome |
|---|---|
Marked microcephaly with intracranial calcifications | Normal or mild brain volume loss without calcifications |
Maternal Zika virus infection during pregnancy | Maternal alcohol use during pregnancy |
Infectious congenital syndrome with neuroinflammation and brain damage | Noninfectious developmental disorder without progressive brain injury |
Congenital Zika Syndrome (Zika Virus) versus Neonatal Herpes Simplex Virus (HSV) Infection
Congenital Zika Syndrome (Zika Virus) | Neonatal Herpes Simplex Virus (HSV) Infection |
|---|---|
Diffuse cortical thinning and calcifications | Temporal lobe hemorrhagic necrosis and edema |
Maternal Zika virus infection during early pregnancy | Maternal genital HSV infection near delivery |
Positive Zika virus RNA by RT-PCR in maternal or infant serum or urine | Positive HSV PCR from CSF or skin lesions |